Rituximab in Relapsing and Progressive Forms of Multiple Sclerosis: A Systematic Review

BACKGROUND: Rituximab is an anti-CD20 monoclonal antibody approved for non Hodgkin lymphoma and rheumatoid arthritis. It is being considered for the treatment of MS. OBJECTIVES: To evaluate the efficacy and safety of rituximab for MS treatment. DATA COLLECTION: Studies were selected if they were cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Castillo-Trivino, Tamara, Braithwaite, Dejana, Bacchetti, Peter, Waubant, Emmanuelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699597/
https://www.ncbi.nlm.nih.gov/pubmed/23843952
http://dx.doi.org/10.1371/journal.pone.0066308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699597/
https://www.ncbi.nlm.nih.gov/pubmed/23843952
http://dx.doi.org/10.1371/journal.pone.0066308

Ejemplares similares